JP2013517461A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013517461A5 JP2013517461A5 JP2012548241A JP2012548241A JP2013517461A5 JP 2013517461 A5 JP2013517461 A5 JP 2013517461A5 JP 2012548241 A JP2012548241 A JP 2012548241A JP 2012548241 A JP2012548241 A JP 2012548241A JP 2013517461 A5 JP2013517461 A5 JP 2013517461A5
- Authority
- JP
- Japan
- Prior art keywords
- expression
- her1
- kit
- level
- vegfr2
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004027 cells Anatomy 0.000 claims 13
- 102100013180 KDR Human genes 0.000 claims 12
- 102100010782 EGFR Human genes 0.000 claims 10
- 101700039191 EGFR Proteins 0.000 claims 10
- 101700075868 HER1 Proteins 0.000 claims 10
- 101700067249 POP2 Proteins 0.000 claims 10
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 claims 10
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 claims 10
- 101710030888 KDR Proteins 0.000 claims 9
- 239000000284 extract Substances 0.000 claims 9
- 239000002246 antineoplastic agent Substances 0.000 claims 5
- 208000000409 Breast Neoplasms Diseases 0.000 claims 4
- 206010006187 Breast cancer Diseases 0.000 claims 4
- 238000004166 bioassay Methods 0.000 claims 4
- 238000001514 detection method Methods 0.000 claims 4
- 210000004881 tumor cells Anatomy 0.000 claims 4
- RCINICONZNJXQF-MZXODVADSA-N Intaxel Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 3
- 108091007928 VEGF receptors Proteins 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 102100001248 AKT1 Human genes 0.000 claims 2
- 101700006234 AKT1 Proteins 0.000 claims 2
- 102000004190 Enzymes Human genes 0.000 claims 2
- 108090000790 Enzymes Proteins 0.000 claims 2
- 101700083887 MAPK1 Proteins 0.000 claims 2
- 102100016823 MAPK1 Human genes 0.000 claims 2
- 229960001592 Paclitaxel Drugs 0.000 claims 2
- 230000004913 activation Effects 0.000 claims 2
- 238000004164 analytical calibration Methods 0.000 claims 2
- 238000011088 calibration curve Methods 0.000 claims 2
- 238000003018 immunoassay Methods 0.000 claims 2
- -1 p95HER2 Proteins 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 230000011664 signaling Effects 0.000 claims 2
- 229930003347 taxol Natural products 0.000 claims 2
- 102000010400 1-phosphatidylinositol-3-kinase activity proteins Human genes 0.000 claims 1
- 108040005185 1-phosphatidylinositol-3-kinase activity proteins Proteins 0.000 claims 1
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 claims 1
- 101710027066 ALB Proteins 0.000 claims 1
- 102100001249 ALB Human genes 0.000 claims 1
- 229940120638 Avastin Drugs 0.000 claims 1
- 108010005144 Bevacizumab Proteins 0.000 claims 1
- 210000004369 Blood Anatomy 0.000 claims 1
- 206010055113 Breast cancer metastatic Diseases 0.000 claims 1
- OLESAACUTLOWQZ-UHFFFAOYSA-L Carboplatin Chemical compound O=C1O[Pt]([N]([H])([H])[H])([N]([H])([H])[H])OC(=O)C11CCC1 OLESAACUTLOWQZ-UHFFFAOYSA-L 0.000 claims 1
- 229960004562 Carboplatin Drugs 0.000 claims 1
- 208000005443 Circulating Neoplastic Cells Diseases 0.000 claims 1
- 102100002605 EIF4EBP1 Human genes 0.000 claims 1
- 101710022869 EIF4EBP1 Proteins 0.000 claims 1
- 102100016662 ERBB2 Human genes 0.000 claims 1
- 101700025368 ERBB2 Proteins 0.000 claims 1
- 102000027776 ERBB3 Human genes 0.000 claims 1
- 101700041204 ERBB3 Proteins 0.000 claims 1
- 102100009851 ERBB4 Human genes 0.000 claims 1
- 101700023619 ERBB4 Proteins 0.000 claims 1
- 101710030892 FLT1 Proteins 0.000 claims 1
- 102100006565 FLT1 Human genes 0.000 claims 1
- 102100013182 FLT4 Human genes 0.000 claims 1
- 101710030894 FLT4 Proteins 0.000 claims 1
- 108040008097 MAP kinase activity proteins Proteins 0.000 claims 1
- 102000019149 MAP kinase activity proteins Human genes 0.000 claims 1
- 101700072814 MPK12 Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 108060006638 PDPK1 Proteins 0.000 claims 1
- 102100018803 PDPK1 Human genes 0.000 claims 1
- 108010011536 PTEN Phosphohydrolase Proteins 0.000 claims 1
- 102000014160 PTEN Phosphohydrolase Human genes 0.000 claims 1
- 210000002381 Plasma Anatomy 0.000 claims 1
- 101710037934 QRSL1 Proteins 0.000 claims 1
- 101700018107 SGK3 Proteins 0.000 claims 1
- 102100018046 SGK3 Human genes 0.000 claims 1
- 210000002966 Serum Anatomy 0.000 claims 1
- 229940050528 albumin Drugs 0.000 claims 1
- 229960000397 bevacizumab Drugs 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 239000000539 dimer Substances 0.000 claims 1
- 101710024775 erkB Proteins 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 230000002934 lysing Effects 0.000 claims 1
- 230000002688 persistence Effects 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 230000004083 survival Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 210000001519 tissues Anatomy 0.000 claims 1
Claims (16)
- 抗癌剤による治療法に対するトリプルネガティブ乳腺腫瘍の反応を予測するための方法であって、
(a)トリプルネガティブ乳腺腫瘍から得られた腫瘍細胞を溶解して、細胞抽出物を作製するステップと、
(b)細胞抽出物におけるVEGFR2の発現レベルを決定するステップと、
(c)ステップ(b)において決定された細胞抽出物におけるVEGFR2の発現レベルを、VEGFR2の参照発現レベルと比較するステップとを含み、
細胞抽出物における参照発現レベルと比較して低レベルのVEGFR2発現の存在が、抗癌剤による治療法に対する反応を予測し、
抗癌剤が、ベバシズマブ(アバスチン(登録商標))、カルボプラチン及びパクリタキセルの組み合わせである、方法。 - ステップ(b)が、細胞抽出物におけるc−KIT、HER1及び/又はIGF−1Rの発現レベルを決定するステップを更に含む、請求項1に記載の方法。
- 細胞抽出物における参照発現レベルと比較して低レベルのc−KIT発現、高レベルのHER1発現及び/又は低レベルのIGF−1R発現の存在が、抗癌剤による治療法に対する反応を予測する、請求項2に記載の方法。
- パクリタキセルが、ナノ粒子アルブミン結合(nab)パクリタキセルである、請求項1〜3のいずれか一項に記載の方法。
- 参照発現レベルが、癌細胞株から作成された検量線から算出され、
前記検量線が、癌細胞株から調製された複数濃度の系列的に希釈された細胞抽出物から作成されてもよく、
前記癌細胞株が、VEGFR2、c−KIT、HER1及び/又はIGF−1Rを発現してもよい、請求項1〜4のいずれか一項に記載の方法。 - 細胞抽出物におけるVEGFR2、c−KIT、HER1、IGF−1R及び/又はAKTの活性化レベルを決定するステップを更に含む、請求項1〜5のいずれか一項に記載の方法。
- 細胞抽出物における1つ又は複数の追加的なシグナル伝達分子の発現及び/又は活性化レベルを決定するステップを更に含む、請求項1〜6のいずれか一項に記載の方法。
- 1つ又は複数の追加的なシグナル伝達分子が、HER2、p95HER2、HER3、HER4、PI3K、AKT、MEK、PTEN、SGK3、4E−BP1、ERK2(MAPK1)、ERK1(MAPK3)、PDK1、P70S6K、GSK−3β、Shc、c−MET、VEGFR1、VEGFR3、受容体二量体及びそれらの組み合わせからなる群から選択される、請求項7に記載の方法。
- 腫瘍細胞が、トリプルネガティブ乳腺腫瘍から得られた循環腫瘍細胞又は穿刺吸引(FNA)細胞である、請求項1〜8のいずれか一項に記載の方法。
- 腫瘍細胞が試料から単離され、
前記試料が、トリプルネガティブ転移性乳癌の対象から得られてもよく、
前記試料が、全血、血清、血漿又は腫瘍組織試料であってもよい、請求項1〜9のいずれか一項に記載の方法。 - 低レベルのVEGFR2発現の存在が、より長期の無進行生存(PFS)持続期間を予測する、請求項1〜10のいずれか一項に記載の方法。
- 低レベルのc−KIT発現の存在及び/又は高レベルのHER1発現の存在が、より長期のPFS持続期間を予測する、請求項2〜11のいずれか一項に記載の方法。
- VEGFR2、c−KIT又はHER1単独の発現レベルと比較して、低レベルのc−KIT発現及び/又は高レベルのHER1発現の存在と組み合わせた低レベルのVEGFR2発現の存在が、より長期のPFS持続期間を予測する、請求項2〜10のいずれか一項に記載の方法。
- ステップ(a)の前にトリプルネガティブ乳腺腫瘍から得られた腫瘍細胞を、インビトロで、抗癌剤とインキュベートするステップを更に含む、請求項1〜13のいずれか一項に記載の方法。
- VEGFR2の発現レベルが、VEGFR2の全タンパク質レベルを検出することにより決定されるか、又はVEGFR2の発現レベルが、近接二重検出アッセイにより決定され、
前記近接二重検出アッセイが、協調的酵素増強反応免疫測定法(CEER)であってもよい、請求項1〜14のいずれか一項に記載の方法。 - c−KIT、HER1及び/又はIGF−1Rの発現レベルが、c−KIT、HER1及び/又はIGF−1Rの全タンパク質レベルを検出することにより決定されるか、又はc−KIT、HER1及び/又はIGF−1Rの発現レベルが、近接二重検出アッセイにより決定され、
前記近接二重検出アッセイが、協調的酵素増強反応免疫測定法(CEER)であってもよい、請求項2〜15のいずれか一項に記載の方法。
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29443310P | 2010-01-12 | 2010-01-12 | |
US61/294,433 | 2010-01-12 | ||
US32562410P | 2010-04-19 | 2010-04-19 | |
US61/325,624 | 2010-04-19 | ||
US32860210P | 2010-04-27 | 2010-04-27 | |
US61/328,602 | 2010-04-27 | ||
US35183810P | 2010-06-04 | 2010-06-04 | |
US61/351,838 | 2010-06-04 | ||
PCT/US2011/021026 WO2011088149A2 (en) | 2010-01-12 | 2011-01-12 | Methods for predicting response of triple-negative breast cancer to therapy |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2013517461A JP2013517461A (ja) | 2013-05-16 |
JP2013517461A5 true JP2013517461A5 (ja) | 2014-02-27 |
JP5764144B2 JP5764144B2 (ja) | 2015-08-12 |
Family
ID=44304951
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012548241A Expired - Fee Related JP5764144B2 (ja) | 2010-01-12 | 2011-01-12 | 治療法に対するトリプルネガティブ乳癌の反応を予測するための方法 |
Country Status (16)
Country | Link |
---|---|
US (2) | US9488654B2 (ja) |
EP (1) | EP2524232B1 (ja) |
JP (1) | JP5764144B2 (ja) |
KR (1) | KR20120115390A (ja) |
CN (1) | CN102822676B (ja) |
AU (1) | AU2011205343B2 (ja) |
BR (1) | BR112012017084A2 (ja) |
CA (1) | CA2787225A1 (ja) |
ES (1) | ES2505466T3 (ja) |
HK (1) | HK1178602A1 (ja) |
IL (1) | IL220833A0 (ja) |
MX (1) | MX2012008153A (ja) |
NZ (1) | NZ601348A (ja) |
RU (1) | RU2558931C2 (ja) |
WO (1) | WO2011088149A2 (ja) |
ZA (1) | ZA201206019B (ja) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101317809B1 (ko) | 2011-06-07 | 2013-10-16 | 한미약품 주식회사 | 암세포의 성장을 억제하는 아마이드 유도체 및 비금속염 활택제를 포함하는 약학 조성물 |
WO2013086031A1 (en) * | 2011-12-05 | 2013-06-13 | Nestec S.A. | Method of therapy selection for patients with cancer |
SG11201403927XA (en) | 2012-01-13 | 2014-08-28 | Genentech Inc | Biological markers for identifying patients for treatment with vegf antagonists |
CA2871385A1 (en) * | 2012-06-26 | 2014-01-03 | F. Hoffmann-La Roche Ag | Blood plasma biomarkers for bevacizumab combination therapies for treatment of breast cancer |
US9422602B2 (en) | 2012-08-15 | 2016-08-23 | Bio-Rad Laboratories, Inc. | Methods and compositions for determining nucleic acid degradation |
WO2014071218A2 (en) * | 2012-11-02 | 2014-05-08 | University Of Utah Research Foundation | Biomarkers for breast cancer and methods of using same |
KR20140096571A (ko) | 2013-01-28 | 2014-08-06 | 한미약품 주식회사 | 1-(4-(4-(3,4-디클로로-2-플루오로페닐아미노)-7-메톡시퀴나졸린-6-일옥시)피페리딘-1-일)프로프-2-엔-1-온의 제조방법 |
EP3039429B1 (en) * | 2013-08-30 | 2018-10-10 | Nestec S.A. | Polyp recurrence |
EP3083686B2 (en) * | 2013-12-17 | 2023-03-22 | F. Hoffmann-La Roche AG | Methods of treating cancers using pd-1 axis binding antagonists and taxanes |
EP3006940A1 (en) * | 2014-10-10 | 2016-04-13 | Ruprecht-Karls-Universität Heidelberg | Biomarkers for predicting the response to anti-angiogenic cancer therapy |
CN105891496A (zh) * | 2014-12-09 | 2016-08-24 | 上海华盈生物医药科技有限公司 | 酪氨酸激酶抑制剂类靶向用药指导抗体芯片和检测方法 |
CN104830775B (zh) * | 2015-04-14 | 2019-06-21 | 上海中医药大学附属龙华医院 | 一种三阴性乳腺癌顺铂耐药细胞株及其制备方法和用途 |
CN107771076A (zh) | 2015-06-17 | 2018-03-06 | 豪夫迈·罗氏有限公司 | 使用pd‑1轴结合拮抗剂和紫杉烷治疗局部晚期或转移性乳腺癌的方法 |
US20180303830A1 (en) * | 2015-06-22 | 2018-10-25 | Thomas Jefferson University | Cancers expressing ccr5 and methods of treatment of same |
EP3363911A4 (en) | 2015-10-14 | 2019-04-03 | Nitto Boseki Co., Ltd | METHOD FOR DETERMINING HUMAN SENSITIVE CELLULAR LINES TO A MEDICINE BY A METHOD OF ANALYSIS USING A MEASUREMENT OF THE ACTIVITY OF TWO TYPES OF PROTEIN KINASE |
RU2616533C1 (ru) * | 2016-03-15 | 2017-04-17 | Федеральное государственное бюджетное научное учреждение "Томский научно-исследовательский институт онкологии" (Томский НИИ онкологии) | Способ прогнозирования эффективности терапии эверолимусом у больных метастатическим раком почки |
IL245861A0 (en) | 2016-05-25 | 2016-09-04 | Yeda Res & Dev | Use of substances to treat drug-resistant tumors |
JP2019519772A (ja) * | 2016-05-31 | 2019-07-11 | ネステク ソシエテ アノニム | Her2及びher3の経路サブタイピングに基づく乳癌患者の薬物療法の選択方法 |
CN106645728A (zh) * | 2016-11-09 | 2017-05-10 | 百奥森(江苏)食品安全科技有限公司 | 一种食品中氟喹诺酮类药物的检测试剂盒 |
RU2648523C1 (ru) * | 2017-05-22 | 2018-03-26 | Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр" Российской академии наук ("Томский НИМЦ") | Способ прогнозирования исхода заболевания у больных люминальным в и трижды негативным раком молочной железы у пациенток, не получавших в неоадъювантном режиме химио- или гормонотерапию |
CN109470854B (zh) * | 2017-09-08 | 2022-02-11 | 广州市丹蓝生物科技有限公司 | 肺癌诊断用蛋白芯片及试剂盒 |
US20210088523A1 (en) * | 2019-09-23 | 2021-03-25 | Sri International | Methods for detecting circulating tumor cells in non-small cell lung cancer |
EP4271995A1 (en) | 2020-12-31 | 2023-11-08 | Elephas Biosciences Corporation | Ex vivo systems and methods for determining the effect of a drug or other agent on a tissue |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5532138A (en) | 1990-04-26 | 1996-07-02 | Behringwerke Ag | Method and kits for determining peroxidatively active catalysts |
US5332662A (en) | 1992-07-31 | 1994-07-26 | Syntex (U.S.A.) Inc. | Methods for determining peroxidatively active substances |
ATE177842T1 (de) | 1993-09-03 | 1999-04-15 | Behringwerke Ag | Fluoreszenz-sauerstoffkanalisation-immunteste |
US5807522A (en) | 1994-06-17 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for fabricating microarrays of biological samples |
US6780582B1 (en) | 1998-07-14 | 2004-08-24 | Zyomyx, Inc. | Arrays of protein-capture agents and methods of use thereof |
US6897073B2 (en) | 1998-07-14 | 2005-05-24 | Zyomyx, Inc. | Non-specific binding resistant protein arrays and methods for making the same |
US6197599B1 (en) | 1998-07-30 | 2001-03-06 | Guorong Chin | Method to detect proteins |
US7179638B2 (en) | 1999-07-30 | 2007-02-20 | Large Scale Biology Corporation | Microarrays and their manufacture by slicing |
US20020076727A1 (en) | 2000-08-03 | 2002-06-20 | Cardone Michael H. | Microarrays of functional biomolecules and uses therefor |
AU2002303384A1 (en) | 2001-04-17 | 2002-10-28 | William J. Dower | Epitope-captured antibody display |
US20030153013A1 (en) | 2002-11-07 | 2003-08-14 | Ruo-Pan Huang | Antibody-based protein array system |
US20060263837A1 (en) | 2004-06-17 | 2006-11-23 | Liu George D | Immunoassay system and method for detection of antigens |
CN105288630A (zh) * | 2005-02-18 | 2016-02-03 | 阿布拉科斯生物科学有限公司 | 治疗剂的组合和给予方式以及联合治疗 |
US7771955B2 (en) | 2005-06-09 | 2010-08-10 | University Of Maryland | Affinity membrane for capture of a target biomolecule and formation thereof by site-directed immobilization of a capture biomolecule |
KR101485303B1 (ko) * | 2006-09-21 | 2015-01-22 | 네스텍 소시에테아노님 | 희귀 순환세포 내의 다수의 신호전달인자를 검출하기 위한 항체 기반 분석법 |
RU2341198C2 (ru) * | 2006-11-27 | 2008-12-20 | ФГУ Ростовский научно-исследовательский онкологический институт Росздрава | Способ оценки ангиогенных факторов при химиотерапии рака молочной железы |
EP2109686A2 (en) * | 2007-01-18 | 2009-10-21 | University Of Southern California | Genetic markers for predicting responsiveness to combination therapy |
CA2700665A1 (en) * | 2007-09-24 | 2009-04-02 | Tragara Pharmaceuticals, Inc. | Combination therapy for the treatment of cancer using cox-2 inhibitors and dual inhibitors of egfr [erbb1] and her-2 [erbb2] |
NZ617520A (en) * | 2008-02-25 | 2015-05-29 | Nestec Sa | Drug selection for breast cancer therapy using antibody-based arrays |
US8071315B2 (en) * | 2008-04-30 | 2011-12-06 | Sanford-Burnham Medical Research Institute | Detecting Bcl-B expression in cancer and uses thereof |
NZ616755A (en) | 2009-05-14 | 2015-05-29 | Nestec Sa | Biomarkers for determining sensitivity of breast cancer cells to her2-targeted therapy |
EP3156800A1 (en) * | 2010-07-19 | 2017-04-19 | F. Hoffmann-La Roche AG | Blood plasma biomarkers for bevacizumab combination therapies for treatment of breast cancer |
-
2011
- 2011-01-12 MX MX2012008153A patent/MX2012008153A/es active IP Right Grant
- 2011-01-12 JP JP2012548241A patent/JP5764144B2/ja not_active Expired - Fee Related
- 2011-01-12 RU RU2012134390/15A patent/RU2558931C2/ru not_active IP Right Cessation
- 2011-01-12 EP EP11733335.1A patent/EP2524232B1/en active Active
- 2011-01-12 CA CA2787225A patent/CA2787225A1/en not_active Abandoned
- 2011-01-12 BR BR112012017084A patent/BR112012017084A2/pt not_active IP Right Cessation
- 2011-01-12 CN CN201180013380.7A patent/CN102822676B/zh not_active Expired - Fee Related
- 2011-01-12 AU AU2011205343A patent/AU2011205343B2/en not_active Ceased
- 2011-01-12 NZ NZ601348A patent/NZ601348A/en not_active IP Right Cessation
- 2011-01-12 WO PCT/US2011/021026 patent/WO2011088149A2/en active Application Filing
- 2011-01-12 ES ES11733335.1T patent/ES2505466T3/es active Active
- 2011-01-12 KR KR1020127021091A patent/KR20120115390A/ko not_active Application Discontinuation
-
2012
- 2012-07-09 IL IL220833A patent/IL220833A0/en unknown
- 2012-07-10 US US13/545,947 patent/US9488654B2/en not_active Expired - Fee Related
- 2012-08-10 ZA ZA2012/06019A patent/ZA201206019B/en unknown
-
2013
- 2013-05-06 HK HK13105383.9A patent/HK1178602A1/xx not_active IP Right Cessation
-
2016
- 2016-09-20 US US15/270,998 patent/US10697967B2/en active Active
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2013517461A5 (ja) | ||
RU2012134390A (ru) | Способы предсказания ответа трижды негативного рака молочной железы на терапию | |
Li et al. | The association between CD8+ tumor-infiltrating lymphocytes and the clinical outcome of cancer immunotherapy: A systematic review and meta-analysis | |
JP2011514522A5 (ja) | ||
JP2012533738A5 (ja) | ||
Tol et al. | Circulating tumour cells early predict progression-free and overall survival in advanced colorectal cancer patients treated with chemotherapy and targeted agents | |
JP2012526992A5 (ja) | ||
Manzoni et al. | Immunological effects of bevacizumab-based treatment in metastatic colorectal cancer | |
Jayson et al. | Antiangiogenic therapy—evolving view based on clinical trial results | |
EP2788752B1 (en) | Method of therapy selection for patients with lung cancer | |
JP2015505959A5 (ja) | ||
US20110275096A1 (en) | Detection of Activation of Endothelial Cells as Surrogate Marker for Angiogenesis | |
JP2015537210A5 (ja) | ||
Hayes et al. | The next steps in next-gen sequencing of cancer genomes | |
Metropulos et al. | The difficulty in translating the preclinical success of combined TGFβ and immune checkpoint inhibition to clinical trial | |
Manzoni et al. | Circulating endothelial cells and their apoptotic fraction are mutually independent predictive biomarkers in Bevacizumab-based treatment for advanced colorectal cancer | |
Kruger et al. | Translational research in pancreatic ductal adenocarcinoma: current evidence and future concepts | |
Blauwhoff-Buskermolen et al. | ‘Pre-cachexia’: a non-existing phenomenon in cancer? | |
Zhang et al. | Predictive biomarkers for the efficacy of cetuximab combined with cisplatin and capecitabine in advanced gastric or esophagogastric junction adenocarcinoma: a prospective multicenter phase 2 trial | |
Troppan et al. | The clinical significance of fibrinogen plasma levels in patients with diffuse large B cell lymphoma | |
WO2010096734A3 (en) | B7-h3 antibody coupled bead assay for detection of circulating tumor cells | |
Li et al. | Multifunctional gold nanoparticle based selective detection of esophageal squamous cell carcinoma cells using resonance Rayleigh scattering assay | |
WO2019066620A3 (ko) | 항 c-met 항체 및 이의 용도 | |
Arjaans et al. | Bevacizumab-Induced Vessel Normalization Hampers Tumor Uptake of Antibodies—Response | |
Wang et al. | Glutamine deprivation impairs function of infiltrating CD8+ T cells in hepatocellular carcinoma by inducing mitochondrial damage and apoptosis |